Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children
Open Access
- 1 January 2021
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Revista do Instituto de Medicina Tropical de São Paulo
Abstract
Twenty-seven children aged seven months to 5 years were inadvertently vaccinated with a COVID-19 vaccine, the CoronaVac (Sinovac, China), an inactivated SARS-CoV-2 vaccine, in two different cities of Sao Paulo State, Brazil. After the event, these children were monitored by local pediatricians and serum samples were collected at the first visit and 30 days after vaccination and tested for SARS-CoV-2 Si serology with Ortho total IgG anti-S1 protein and Cpass, an ACE2 receptor binding domain inhibition assay. Only one child had a mild symptom after vaccination, with no other adverse events documented up to the 30 days follow-up. Of 27 children tested 3-9 days after vaccination, 5 (19%) had positive serology suggesting a previous natural SARS-CoV-2 infection, with all 19 tested on day 30 after vaccination and presenting with positive tests, with an increment of antibody titers in those initially positive. A low Cpass binding inhibition was observed in the first collection in 11 seronegative cases, with high titers among those anti-S1 positive. All children showed an important increase in antibody titers on day 30. The event allowed the documentation of a robust serological response to one dose of CoronaVac in this small population of young children, with no major adverse effects. Although it was an unfortunate accident, this event may contribute with future vaccine strategies in this age group. The data suggest that CoronaVac is safe and immunogenic for children.Keywords
This publication has 9 references indexed in Scilit:
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trialThe Lancet Infectious Diseases, 2021
- A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response DetectionJournal of Clinical Microbiology, 2021
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trialThe Lancet Infectious Diseases, 2020
- Children and Adolescents With SARS-CoV-2 InfectionThe Pediatric Infectious Disease Journal, 2020
- Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assaysPathology, 2020
- Multisystem Inflammatory Syndrome in Children (MIS-C) with COVID-19: Insights from simultaneous familial Kawasaki Disease casesInternational Journal of Infectious Diseases, 2020
- The Importance of Advancing Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in ChildrenClinical Infectious Diseases, 2020
- Coronavirus Infections in Children Including COVID-19The Pediatric Infectious Disease Journal, 2020
- Prevalence and types of vaccination errors from 2009 to 2018: A systematic review of the medical literatureVaccine, 2019